Multiple intracranial and spinal metastases from a nonfunctioning pituitary adenoma following multiple surgeries: an illustrative case with 16 years of follow-up
© Wang et al.; licensee BioMed Central Ltd. 2014
Received: 6 September 2014
Accepted: 3 December 2014
Published: 12 December 2014
Pituitary adenomas are the third most common primary intracranial tumor; however, those with postoperative metastases are very rare and are classically considered as pituitary carcinomas. The field of neurosurgery has struggled with diagnosing and treating these unusual lesions. In this report, we retrospectively analyze the clinical features, imaging findings, pathological characteristics and prognosis of one patient with non-hormone-secreting pituitary adenoma who had multiple intracranial and spinal metastases and underwent four surgeries in a 16-year follow-up period. In addition, on the basis of the existing literature, we explore the underlying mechanisms of, as well as the preventive and therapeutic strategies used to treat, pituitary carcinomas and postoperative metastasis of pituitary tumors.
Pituitary adenomas are very common and rank third in terms of incidence among all primary intracranial tumors. However, primary pituitary adenomas with intracranial or extracranial metastases are very rare and are commonly defined as malignant pituitary tumors or pituitary carcinomas [1–7]. The field of neurosurgery has struggled with the diagnosis and treatment of these unusual lesions. In general, the prognosis of this disease is not optimistic. Therefore, it demands an early diagnosis and effective therapies. In this report, we present the case of one patient with non-hormone-secreting pituitary adenoma who had multiple intracranial and spinal metastases and underwent four surgeries in a 16-year period. In addition, on the basis of a literature review, we discuss the diagnostic, preventive and therapeutic strategies for malignant pituitary adenoma and postoperative metastasis of pituitary tumors.
Laboratory and neuroimaging examinations
In the patient’s fourth surgery, the right subfrontal approach of craniotomy was adopted, and the incision was made at the same site used in the first surgery in 1998. After we expanded the bone window to the middle line and attempted to cut the dura mater open, we observed the dura mater to be tightly adhered to the right frontal cortex, which was then carefully dissociated under a microscope. During the dissociation process, we first exposed and removed the lesion in the right frontal lobe. The lesion was gray and soft, with a base connected to the dura mater. The lesion was immediately sent for intraoperative pathological examination, and the diagnosis was neuroendocrine neoplasm. Subsequently, we dissociated and removed the tumor in the sellar region. We then exposed and resected the tumor at the cerebral falx using an interhemispheric fissure approach. After the surgery, the patient had a satisfactory recovery of visual field, but experienced transient diabetes insipidus and hypopituitarism, from which he gradually recovered after symptomatic treatment. No other operation-related complications occurred. The postoperative MRI demonstrated complete removal of three lesions. Whole-brain and spine radiotherapy in combination with chemotherapy were suggested to the patient, but he rejected this suggestion.
The patient was followed from December 1998 (after the first surgery) to December 2014. He achieved a satisfactory recovery after each surgery. No tumor recurrences or metastatic lesions were observed in the sellar region or other regions during the 19-month follow-up period from May 2013 (after the fourth surgery) to December 2014.
Pituitary tumors are very common, and most are benign. The World Health Organization (WHO) classification of tumors of the central nervous system (2000) categorizes pituitary tumors into three grades: benign, intermediate or atypical, and malignant . It is worth noting that the pathological classification assigned should be closely associated with clinical biological behaviors. Therefore, the WHO standards state that, even if pathological analyses reveal that the primary or metastatic lesion of pituitary tumor that has metastasized to subarachnoid space or extracranial sites is benign, it still belongs to the malignant pituitary tumor classification for its aggressive biological behavior [7–12]. Pituitary carcinoma, the most common form of malignant pituitary tumors, is also defined by the presence of a pituitary tumor that either is not contiguous with the primary sellar tumor and/or is not a pituitary tumor that has metastasized to sites distant from the pituitary [2, 4, 13]. This terminology is commonly used for describing the malignant pituitary adenoma. Currently, there is still controversy regarding the initiation and progression of pituitary carcinoma, the focus of which is whether it develops from benign adenomas or occurs de novo and whether the hormonal subtype does affect tumor aggressiveness, treatment outcome and prognosis . Although the progression from benign pituitary adenomas to carcinomas has often been considered [1, 6, 14, 15], the detailed mechanisms underlying this phenomenon are still unclear and may involve multiple molecular events.
A literature review revealed that pituitary carcinoma is very uncommon and accounts for only approximately 0.1% to 0.2% of all pituitary tumors [2, 3, 15–17]. According to a recent study, most of the reported pituitary carcinomas are functional (83%), with 35% of the lesions producing ACTH, 33% PRL, 9% growth hormone (GH), 4% luteinizing hormone (LH) and/or follicle-stimulating hormone (FSH), and only 1% TSH . Nonfunctioning tumors represent 19% of all cases, also including silent ACTH, FSH, LH and rare null-cell pituitary carcinomas . Similar results were reported in another study, with the majority (36%) of the hormonally active tumors producing PRL; 30% secreting ACTH; 5% producing GH; 2% producing TSH, gonadotropin-releasing hormone or LH; and 23% not secreting any hormones . The endocrine parameters (hormone in blood serum) in the case of our patient were clinically normal. However, the immunopathological examination revealed positive ACTH staining. Hence, the possibility of an ACTH adenoma that did not affect endocrine function could not be ruled out clinically. As reported previously, corticotrophic carcinomas develop in the setting of “silent” corticotrophic tumors in approximately 25% cases . Similarly, it remains unclear whether a metastatic functional pituitary adenoma can possess endocrine function.
The spread pathway of tumor cells from a pituitary carcinoma has not been determined, but has been proposed to be varied, including cerebrospinal fluid circulation and lymphatic or hematogenous metastasis to extracranial sites [19, 20]. The metastasis of pituitary carcinomas might be related to the biological properties of tumors, such as invasion, as well as to the surgical procedures used. According to the existing literature, the metastases of pituitary tumors mostly occur after surgery, in particular after craniotomy. As reported by Tanaka et al., the development of metastases followed surgery performed for primary pituitary tumors in 21 (70%) of 30 cases . Therefore, it was suggested that surgery may precipitate postoperative metastasis of pituitary adenomas. From a neurosurgeon’s point of view, this may be due to several reasons. First, neurosurgery, especially a craniotomy, not only can rupture the tumor capsule but also can injure the normal arachnoid membrane, creating favorable conditions for the spread of tumor cells along the subarachnoid space. Second, the vessels of or around the tumor are destroyed, which may enhance hematogenous metastasis. Third, tumor cells may be disseminated by the surgical instruments or flush water. Moreover, we noticed that most patients with postoperative metastases of pituitary tumors reported in the literature underwent craniotomies before 2000 [5, 9–12, 22–27]. After 2000, because of the progress made with the use of the endonasal transsphenoidal surgical technique, this approach has been applied in more than 90% of pituitary tumor surgeries. The endonasal transsphenoidal approach rarely causes a massive cerebrospinal fluid leakage or tumor cell dissemination to the subarachnoid space, and, as a result, the possibility of surgery-associated postoperative tumor metastasis in the subarachnoid space is significantly reduced. On the basis of this analysis, it is indicated that postoperative metastasis of pituitary tumors may be closely related to the surgical methods employed. However, the discussion above lacks the support of randomized controlled studies with large sample sizes. Moreover, the case sample with postoperative pituitary tumor metastasis is relatively low. Therefore, the analyses above are clinical inferences that require further verification.
The treatment for pituitary carcinoma should be comprehensive, including neurosurgery, radiotherapy, chemotherapy and medical therapy [1–3, 15–17]. Neurosurgery has been considered to be the first line treatment for pituitary carcinoma, for it not only can relieve the clinical symptoms by removing the lesions but also can aid in the diagnosis by providing pathological samples [1, 2, 15]. Although it is considered that surgery alone is rarely curative, especially for patients with multiple intracranial or systemic metastases, it should be pointed out that surgery can notably prolong survival in some cases . Our patient is a case in point, because he underwent four surgeries in the 16-year follow-up period and had a satisfactory recovery after each surgery. Individualized surgical plans should be developed for the treatment of pituitary carcinoma, including transsphenoidal surgery, transcranial surgery and combined surgeries. Transsphenoidal surgery may be preferable in most cases, except for those with multiple intracranial metastatic lesions or large pituitary carcinomas with invasiveness into parasellar structures, for whom transcranial surgery should be recommended.
In our patient, three intracranial lesions were found in the MRI examination. Because all the lesions were located supratentorially, a one-stage transcranial operation was performed to remove all three lesions simultaneously. Furthermore, although the lesions were intracranial, they were all located at sites outside the brain; therefore, it was feasible to remove the lesions with minimal invasion of the brain tissue. The outcome of the surgery was satisfactory, with no serious postoperative complications. After surgery, radiation therapy, such as fractionated radiation therapy, stereotactic radiosurgery and whole-brain or spinal radiation, should be administered in most cases to prevent tumor relapse [1, 2, 15, 29]. In patients with tumors subtotally resected or with multiple intracranial metastases, radiation therapy should be performed earlier to slow growth of the tumor and/or metastatic deposits. Clinically, radiation therapy has been suggested to be effective in achieving local control or slowing tumor growth in some cases [1, 15, 29]. However, because these results lack evidence derived from randomized controlled trials, the usefulness of radiation therapy should be determined in further studies.
Chemotherapy is commonly used in the treatment of many types of carcinomas; however, its application in the treatment of pituitary carcinoma is just now being tested. The most commonly used drugs are temozolomide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in combination with 5-fluorouracil [2, 30]. Other agents used include cisplatin, etoposide, cyclophosphamide, adriamycin, methotrexate, vinblastine and bleomycin. Although various chemotherapy protocols have been applied in the treatment of pituitary carcinomas, no significant effect on tumor size or secretion and only transient improvement or stabilization have been observed in a minority of patients [1, 15]. More important, because of the rarity of these lesions, the potential use of chemotherapeutic drugs in the treatment of pituitary carcinoma has not been verified in multicenter randomized controlled trials. Therefore, similarly to radiotherapy, the usefulness of chemotherapy also needs to be validated by future studies. Medical therapy, such as with bromocriptine and cabergoline, has been considered as the first-line treatment for functional pituitary adenomas (benign). In pituitary carcinomas, medical therapy has been used to control excess hormone secretion and/or tumor proliferation. Currently, the most widely used clinical drugs include dopamine agonists, octreotide and lanreotide, which have been used to treat PRL-, GH-, ACTH- and TSH-secreting pituitary carcinomas [1, 2, 15]. However, the clinical benefit was reported to be minimal. In general, the efficacy of medical therapy for pituitary carcinomas still needs to be determined. Future improvements in targeted molecular therapies (biotherapy or gene therapies) and immunotherapy may provide more effective options for treatment of malignant pituitary tumors.
Pituitary carcinoma is very rare. The recommended treatment regimens are comprehensive, including neurosurgery, radiotherapy, chemotherapy and medical therapy. Scientific and professional follow-up is conducive to the early detection of tumor recurrence or postoperative pituitary tumor metastasis. To date, the effectiveness of treatments has not been satisfactory. Future progress in targeted therapy and immunotherapy may provide more effective treatments for this rare malignant lesion.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank all the staff members in the Neurosurgery Department of the First Hospital of China Medical University for their technical help. This study was supported by the National Natural Science Foundation of China (no. 31100770 (to JW)), the Liaoning Provincial Natural Science Foundation of China (no. 2014021097 (to JW) and no. 2013021075 (to BQ)) and the Fund for Scientific Research of the First Hospital of China Medical University (no. fsfh1304 (to BQ)).
- Colao A, Ochoa AS, Auriemma RS, Faggiano A, Pivonello R, Lombardi G: Pituitary carcinomas. Front Horm Res. 2010, 38: 94-108.View ArticlePubMedGoogle Scholar
- Heaney AP: Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab. 2011, 96: 3649-3660. 10.1210/jc.2011-2031. A published erratum appears in J Clin Endocrinol Metab 2012, 97:1064PubMed CentralView ArticlePubMedGoogle Scholar
- Ragel BT, Couldwell WT: Pituitary carcinoma: a review of the literature. Neurosurg Focus. 2004, 16: E7-View ArticlePubMedGoogle Scholar
- Amar AP, Hinton DR, Krieger MD, Weiss MH: Invasive pituitary adenomas: significance of proliferation parameters. Pituitary. 1999, 2: 117-122. 10.1023/A:1009931413106.View ArticlePubMedGoogle Scholar
- Depper MH, Carlow TJ, Crooks LA, Orrison WW: Intracranial dissemination of a pituitary adenoma: presentation as an unusual mass in the cerebellopontine angle. AJR Am J Roentgenol. 1996, 166: 1500-1501. 10.2214/ajr.166.6.8633483.View ArticlePubMedGoogle Scholar
- Kameya T: Malignant pituitary tumors. Pathol Res Pract. 1988, 183: 620-622. 10.1016/S0344-0338(88)80025-6.View ArticlePubMedGoogle Scholar
- Solcia E, Klöppel G, Sobin LH: Histological Typing of Endocrine Tumours. 2000, Berlin: Springer, 17-2View ArticleGoogle Scholar
- Lehman NL, Horoupian DS, Harsh GR: Synchronous subarachnoid drop metastases from a pituitary adenoma with multiple recurrences: case report. J Neurosurg. 2003, 98: 1120-1123. 10.3171/jns.2003.98.5.1120.View ArticlePubMedGoogle Scholar
- Giordana MT, Cavalla P, Allegranza A, Pollo B: Intracranial dissemination of pituitary adenoma: case report and review of the literature. Ital J Neurol Sci. 1994, 15: 195-200. 10.1007/BF02339323.View ArticlePubMedGoogle Scholar
- Kouhara H, Tatekawa T, Koga M, Hiraga S, Arita N, Mori H, Sato B: Intracranial and intraspinal dissemination of an ACTH-secreting pituitary tumor. Endocrinol Jpn. 1992, 39: 177-184. 10.1507/endocrj1954.39.177.View ArticlePubMedGoogle Scholar
- Kumar K, Kelly M: Benign pituitary adenoma with multiple dural metastases: a case report. Surg Neurol. 2000, 54: 380-384. 10.1016/S0090-3019(00)00325-6.View ArticlePubMedGoogle Scholar
- Shimizu K, Takamiya Y, Furuhata S, Naritaka H, Kameya T: Cystic lesion at the foramen magnum disseminated from a pituitary adenoma—case report. Neurol Med Chir (Tokyo). 1999, 39: 606-611. 10.2176/nmc.39.606.View ArticleGoogle Scholar
- Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996, 38: 99-107. 10.1097/00006123-199601000-00024.View ArticlePubMedGoogle Scholar
- Clayton RN, Farrell WE: Clonality of pituitary tumours: more complicated than initially envisaged?. Brain Pathol. 2001, 11: 313-327.View ArticlePubMedGoogle Scholar
- Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005, 90: 3089-3099. 10.1210/jc.2004-2231.View ArticlePubMedGoogle Scholar
- Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF, Lloyd RV, Davis DH, Guthrie BL, Schoene WC: Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer. 1997, 79: 804-812. 10.1002/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3.View ArticlePubMedGoogle Scholar
- Maira G, Doglietto F: Pituitary carcinoma: a devastating disease in need of an earlier diagnosis and of effective therapies. World Neurosurg. 2013, 80: e143-e145. 10.1016/j.wneu.2011.06.025.View ArticlePubMedGoogle Scholar
- Dudziak K, Honegger J, Bornemann A, Horger M, Müssig K: Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course—case report and review of the literature. J Clin Endocrinol Metab. 2011, 96: 2665-2669. 10.1210/jc.2011-1166.View ArticlePubMedGoogle Scholar
- Asai A, Matsutani M, Funada N, Takakura K: Malignant growth hormone-secreting pituitary adenoma with hematogenous dural metastasis: case report. Neurosurgery. 1988, 22: 1091-1094. 10.1227/00006123-198806010-00023.View ArticlePubMedGoogle Scholar
- Matsuki M, Kaji Y, Matsuo M, Kobashi Y: MR findings of subarachnoid dissemination of a pituitary adenoma. Br J Radiol. 2000, 73: 783-785. 10.1259/bjr.73.871.11089473.View ArticlePubMedGoogle Scholar
- Tanaka Y, Tsuda M, Sato M, Kanno H, Tokoro K, Yamamoto I, Kimura S, Kitamura H: [CSF dissemination of a pituitary adenoma: a case report] [Article in Japanese]. Jpn J Neurosurg. 1996, 5: 391-397.Google Scholar
- De Boucaud L, Dousset V, Caillaud P, Viaud B, Guerin J, Caillé JM: Metastases from a pituitary adenoma: MRI. Neuroradiology. 1999, 41: 785-787. 10.1007/s002340050842.View ArticlePubMedGoogle Scholar
- Gasser RW, Finkenstedt G, Skrabal F, Twerdy K, Grunert V, Mayr U, Frommhold H, Zur Nedden D, Feichtinger J, Hofstaedter F: Multiple intracranial metastases from a prolactin secreting pituitary tumour. Clin Endocrinol (Oxf). 1985, 22: 17-27. 10.1111/j.1365-2265.1985.tb01060.x.View ArticleGoogle Scholar
- Taylor WA, Uttley D, Wilkins PR: Multiple dural metastases from a pituitary adenoma: case report. J Neurosurg. 1994, 81: 624-626. 10.3171/jns.1994.81.4.0624.View ArticlePubMedGoogle Scholar
- Coculescu M, Temel E, Oprescu M, Constantinovici A, Carp N, Simiónescu N: Hormonal evidence for the dissemination through the cerebrospinal fluid, of secreting cells from invasive pituitary adenomas. Endocrinologie. 1981, 19: 129-135.PubMedGoogle Scholar
- Cohen DL, Diengdoh JV, Thomas DG, Himsworth RL: An intracranial metastasis from a PRL secreting pituitary tumour. Clin Endocrinol (Oxf). 1983, 18: 259-264. 10.1111/j.1365-2265.1983.tb03210.x.View ArticleGoogle Scholar
- Kuroki M, Tanaka R, Yokoyama M, Shimbo Y, Ikuta F: Subarachnoid dissemination of a pituitary adenoma. Surg Neurol. 1987, 28: 71-76. 10.1016/0090-3019(87)90210-2.View ArticlePubMedGoogle Scholar
- Tanaka T, Kato N, Aoki K, Watanabe M, Arai T, Hasegawa Y, Abe T: Long-term follow-up of growth hormone-producing pituitary carcinoma with multiple spinal metastases following multiple surgeries: case report. Neurol Med Chir (Tokyo). 2013, 53: 707-711. 10.2176/nmc.cr2012-0152.View ArticleGoogle Scholar
- Lopes MB, Scheithauer BW, Schiff D: Pituitary carcinoma: diagnosis and treatment. Endocrine. 2005, 28: 115-121. 10.1385/ENDO:28:1:115.View ArticlePubMedGoogle Scholar
- Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T: Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010, 95: 4592-4599. 10.1210/jc.2010-0644.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.